UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
MARCH 10 2005
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
AGM STATEMENT
ANNUAL GENERAL MEETING AT NOVO NORDISK A/S
At the Annual General Meeting of Novo Nordisk A/S today, the shareholders made
the following resolutions:
* Adoption of the audited Annual Report 2004, including approval of the
remuneration of the Board of Directors.
* Resolution to distribute the profit according to the adopted Annual Report
2004. The dividend will be DKK 4.80 per share of DKK 2, an increase of 9%
compared with 2003.
* Board members elected by the Annual General Meeting: Re-election of Mads
Ovlisen, Sten Scheibye, Kurt Briner, Niels Jacobsen, Kurt Anker Nielsen and
Jorgen Wedel and election of Goran A Ando and Henrik Gurtler.
* Re-election of the auditor, PricewaterhouseCoopers.
* Authorisation to the Board of Directors, until the next Annual General
Meeting, to allow Novo Nordisk A/S to acquire own shares of up to 10% of
the share capital and at the price quoted on the date of purchase with a
deviation of up to 10%, cf Article 48 of the Danish Companies Act.
The Board of Directors
Accordingly the Board of Directors of Novo Nordisk A/S comprises:
* Mads Ovlisen
* Sten Scheibye
* Goran A Ando
* Kurt Briner
* Henrik Gurtler
* Johnny Henriksen (employee representative)
* Niels Jacobsen
* Anne Marie Kverneland (employee representative)
* Kurt Anker Nielsen
* Stig Strobaek (employee representative)
* Jorgen Wedel
For information on the board members, please refer to novonordisk.com.
At a board meeting immediately after the Annual General Meeting, the Board of
Directors constituted itself with Mads Ovlisen as chairman and Sten Scheibye as
vice chairman.
The Board of Directors elected Kurt Anker Nielsen, Niels Jacobsen and Jorgen
Wedel as members of the Audit Committee with Kurt Anker Nielsen as chairman.
Kurt Anker Nielsen and Niels Jacobsen were designated by the Board of Directors
as Audit Committee Financial Experts.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The
company has the broadest diabetes product portfolio in the industry, including
the most advanced products within the area of insulin delivery systems. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 20,250 full-time
employees in 78 countries, and markets its products in 179 countries. Novo
Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.
Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For
more information, visit novonordisk.com.
For further information please contact:
Media: Investors:
Outside North America: Outside North America:
Mike Rulis Mogens Thorsager Jensen
Tel (direct): (+45) 4442 3573 Tel (direct): (+45) 4442 7945
Palle Holm Olesen
Tel (direct): (+45) 4442 6175
In North America: In North America:
Susan T Jackson Christian Kanstrup
Tel (direct): (+1) 609 919 7776 Tel (direct): (+1) 609 919 7937
Stock Exchange Announcement No 13 /2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: MARCH 10 2005 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer